Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Blueprint Genetics | RCV001074899 | SCV001240503 | uncertain significance | Retinal dystrophy | 2019-08-16 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV001233130 | SCV001405712 | uncertain significance | not provided | 2022-06-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CNGB1 protein function. ClinVar contains an entry for this variant (Variation ID: 866680). This variant has not been reported in the literature in individuals affected with CNGB1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.01%). This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 747 of the CNGB1 protein (p.Pro747Thr). |
| Ambry Genetics | RCV004609618 | SCV005109347 | uncertain significance | Inborn genetic diseases | 2024-06-16 | criteria provided, single submitter | clinical testing | The c.2239C>A (p.P747T) alteration is located in exon 23 (coding exon 22) of the CNGB1 gene. This alteration results from a C to A substitution at nucleotide position 2239, causing the proline (P) at amino acid position 747 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |